Perindopril/ramipril/unspecified recombinant tissue plasminogen activator
- PDF / 169,446 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 66 Downloads / 201 Views
1 S
Perindopril/ramipril/unspecified recombinant tissue plasminogen activator Orolingual angioedema: 5 case reports
In a meta-analysis of 548 patients with ischaemic stroke who had undergone thrombolysis with an unspecified recombinant tissue plasminogen activator between January 2004 and December 2008, five patients [2 men and 3 women] aged 61–78 years were described, who developed orolingual angioedema following treatment with ramipril, perindopril or an unspecified recombinant tissue plasminogen activator [dosages not stated; not all indications, routes and durations of treatments to reactions onsets stated]. The patients, who had ischaemic stroke (left middle cerebral artery infarct, posterior cerebral artery bilateral pons infarct or pons infarct), underwent IV thrombolysis with an unspecified recombinant tissue plasminogen activator. Prior to the thrombolysis, the patients had been receiving ramipril (4 patients) and perindopril (1 patient). After 10–60 minutes of thrombolysis, the patients developed orolingual angioedema (sites: bilateral lips or bilateral tongue). Consequently, the 4/5 patients required intubation. The orolingual angioedema lasted for 2h–5days. Berrouschot J, et al. Orolingual angioedema after thrombolysis in stroke. Nervenheilkunde 29: 147-149, No. 3, 2010. Available from: URL: http://doi.org/10.1055/ s-0038-1628732 [German; summarised from a translation]
0114-9954/20/1827-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803508849
Reactions 24 Oct 2020 No. 1827
Data Loading...
